Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I8BH
|
|||
| Former ID |
DIB010798
|
|||
| Drug Name |
Vx-001
|
|||
| Synonyms |
HTERT572Y peptide vaccine (cancer), Vaxon; HLA-A2 monopeptide vaccine (cancer), Vaxon; TERT572 + TERT572Y peptide (cancer), Vaxon
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1] | |
| Company |
Vaxon Biotech SA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Telomerase reverse transcriptase (TERT) | Target Info | . | [2] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Validated targets of C-MYC transcriptional activation | |||
| Regulation of Telomerase | ||||
| IL2 signaling events mediated by PI3K | ||||
| Regulation of nuclear beta catenin signaling and target gene transcription | ||||
| HIF-1-alpha transcription factor network | ||||
| Reactome | Formation of the beta-catenin:TCF transactivating complex | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01935154) Efficacy Study of Vx001 Vaccine in NSCLC Patients. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Vaxon-biotech. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.